Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases 2022-09-26 08:00
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth 2022-09-19 08:00
Everest Medicines Announces the Departure of CEO, Kerry Blanchard 2022-08-26 07:30
Everest Medicines Announces Interim Results for First Half of 2022 2022-08-24 21:10
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories 2022-08-16 07:15
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan 2022-08-11 08:00
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics 2022-07-18 08:00
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics 2022-07-18 08:00
Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer 2022-06-10 11:12
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients 2022-06-04 20:30
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis 2022-05-24 19:00
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis 2022-05-24 19:00
Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business 2022-04-07 07:30
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis 2022-04-06 08:00
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer 2022-03-31 08:00
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential 2022-03-30 08:00
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021 2022-03-29 06:30
Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022 2022-03-15 09:00
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea 2022-03-14 08:00
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial 2022-03-10 19:05
1 2 3 4 5 6 7